Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoimmunotherapy Plus SBRT for Resectable NSCLC
NCT06718309Phase 2Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by Hangzhou First People's Hospital. Primary endpoint: Pathological Complete Response at 24 weeks. Started Apr 2024; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06718309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718309.